NewslettersImmune Regulation News Activist Investors Once Again Take AIM at Biotech Working on Treatment for Long COVID Symptoms By Laurisa Dohm - September 1, 2023 0 Shareholder activists contend that AIM Immunotech has failed to invest enough money into developing its lead asset ampligen. [Fierce Biotech] Press Release